Vitamin D Levels in Female Depressive Psychotic Patients

DALIA R. IBRAHIM, Ph.D.* and EMAN M. MAHMOUD, Ph.D.**

The Department of Biological Applications, Nuclear Research Center, Atomic Energy Authority* and
The Department of Clinical Pathology, Abou Al-Azayem Hospital**, Cairo, Egypt

Abstract

Background: Vitamin D is a neurosteroid hormone of a central role in CNS development and function and its insufficiency is associated with cognitive impairments. Major Depression Disorder (MDD) is a mental disorder that is affected by diet and nutritional factors.

Aim of Study: The present study was carried out to assess the levels of vitamin D in depressive psychotic female patients and to compare its levels with the control group.

Subjects and Methods: Eighty female subjects participated in this study, 40 inpatients in Abou Al-Azayem Psychiatric Hospital, Cairo, Egypt, suffering from major depressive disorder, and 40 healthy control volunteers. Vitamin D concentration, Thyroid stimulating hormone (TSH), Aspartate Aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting glucose were evaluated in serum.

Results: The results showed that vitamin D levels were significantly lower in the depressive psychotic group compared to the control group. Meanwhile, there were significant increases in urea concentrations in the depressive group compared to the control one. The two groups (depressive psychotic and control) on the other hand, showed insignificant changes in TSH, AST, ALT, creatinine and fasting glucose levels.

Conclusion: Depressive psychotic patients suffered from vitamin D deficiency and insufficiency therefore, vitamin D supplementation maybe effective in the treatment of depression and lowering the depressive symptoms.

Key Words: Vitamin D – Psychosis – Major depressive disorder.

Introduction

MAJOR Depression Disorder (MDD) is a worldwide mental disorder that affects the functioning and quality of life and causes health and economic burden [1]. Lifestyle factors such as physical activity and diet quality might be risk factors to mental disorders [2,3]. Vitamin D is one of the nutritional components that might have an important role in mental health [4]. Vitamin D is influenced by many cofactors such as seasonal [5], environmental and genetic factors [6]. Many risk factors cause vitamin D deficiency such as ageing, obesity, female sex, winter season, dark skin pigmentation, anxiety, eating disorders [7-9], impaired liver function, renal and cardiovascular diseases [10,11]. Vitamin D is found in two forms: Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol). Vitamin D2 is available in dietary products such as plants and fish, while vitamin D3 is synthesized in the skin when exposed to Ultraviolet B (UVB) rays from sunlight [12]. The marker of Vitamin D status is serum 25-Hydroxyvitamin D [25-(OH)D], which is the main circulating metabolite of Vitamin D [13], and the US Endocrine Society defines Vitamin D deficiency as 25-(OH)D less than 20ng/ml, Vitamin D insufficiency as 25-(OH)D between 20 and 30ng/ml, and Vitamin D sufficiency as 25-(OH)D greater than 30ng/ml [10].

The presence of Vitamin D [25-(OH)D] in cerebrospinal fluid suggests that Vitamin D may play a role in brain development [14]. Previous studies reported that alterations in serum Vitamin D level are associated with changes in brain volume [15-18]. Moreover, the presence of Vitamin D receptor and vitamin D metabolizing enzymes [19,20] in the human nervous system (CNS) indicates that Vitamin D may have a functional role in the nervous system [21,22]. Vitamin D is involved in signaling cascades and neurobiological pathways [23]. The active metabolite 1,25 (OH)2D3 is thought to regulate the maturation and differentiation of dopaminergic neurons [24] and affect the levels of brain serotonin [23,25]. It is suggested that Vitamin D may have a role in the emotional and cognitive...
functions [21,26,27]. This may indicate that there is an association between serum Vitamin D level, total intracranial volume and the depressive mood. The present study aims at assessing the levels of Vitamin D in female depressive psychotic patients and to compare its levels with the control group.

**Subjects and Methods**

1- Patients:
This study was performed on 80 female subjects divided into two equal groups. The depressive psychotic group, consisted of 40 in patients in Abou Al-Azayem Psychiatric Hospital, Cairo, Egypt (from February to June, 2019), suffering from Major Depressive Disorder (MDD), age ranged from 35 to 48 years, and the control group, consisted of 40 healthy females, age ranged from 37 to 45 years. Clinical psychiatrists confirmed the diagnosis of depression in accordance with the International Classification of Diseases Criteria. All patients were receiving their regular antidepressant medications. Clinical and laboratory examinations were performed to exclude severe somatic diseases, diabetes, liver or renal diseases and overt or subclinical thyroid diseases.

2- Collection of blood samples and biochemical analysis:
After fasting for 6-8 hours, 5ml venous blood was drawn from each participant for laboratory investigations. The blood was centrifuged at 2000xg for 10min. Serum was separated and stored at −80°C until further analysis. Vitamin D level was measured using radioimmunoassay kit (DiaSorin, Stillwater, Minnesota, U.S.A). Quantitative determination of TSH was assayed utilizing RIA kit (MP Biomedicals, China). Fasting glucose was measured using enzymatic technique (Vitro Scientific). The liver enzymes, namely, AST and ALT were measured using kinetic technique (Diaican). Urea and creatinine analyses were carried out using Jaffe Kinetic methods. The apparatus used for biochemical analysis was TICO (USA) semi-automated spectrophotometer. Complete Blood Count (CBC) was carried out using MICROS 3 differential full automated hematology counter (France).

3- Compliance and ethical standards:
All procedures performed involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consents were obtained from all participants after they had been given a complete description of the study.

4- Statistical analysis:
Data were analyzed with the statistical package for social sciences (SPSS, version 20 for windows, Chicago, USA). Results were expressed as percentages (%) or mean ± standard deviation. Paired Student Test (t-test) was carried out for the statistical analysis studies of the mean values of the experimental parameters. p<0.001 was considered statistically significant.

**Results**

In the present study, the age of the control group ranged from 37 to 45 years with mean ± SD (39.80±3.12), while the age of the depressive psychotic group ranged from 35 to 48 years with mean ± SD (41.30±3.81). All the participants were females. Table (1) illustrates the levels of Vitamin D in the controls and the depressive psychotic patients. Among the 40 psychotic patients, 26 patients (65%) were classified as deficient Vitamin D (<20ng/ml) and 14 patients (35%) were classified as insufficient Vitamin D (20-30ng/ml). In the control group, 30 subjects (75%) were classified as sufficient Vitamin D (30-100ng/ml) and 10 subjects (25%) were classified as insufficient Vitamin D.

<table>
<thead>
<tr>
<th>Total Vitamin D</th>
<th>Control (%)</th>
<th>Depressive Psychotic patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deficient &lt;20ng/ml</td>
<td>26 (65%)</td>
<td></td>
</tr>
<tr>
<td>Insufficient 20-30ng/ml</td>
<td>10 (25%)</td>
<td>14 (35%)</td>
</tr>
<tr>
<td>Sufficient 30-100ng/ml</td>
<td>30 (75%)</td>
<td></td>
</tr>
</tbody>
</table>

The analysis of the biochemical parameters in (Table 2) revealed that there were significant decreases in Vitamin D levels in the depressive psychotic group compared to the control group. Meanwhile, the urea concentrations significantly increased in the depressive group compared to the control group, but they are within the normal range. The two groups (depressive psychotic and control) on the other hand, showed insignificant changes in TSH, AST, ALT, creatinine and fasting glucose levels and all their results were within the normal range.
Vitamin D deficiency at 25-(OH) D levels <50nmol/l (<20 ng/ml) was significantly associated with the increase in the depressive symptoms in the hospitalized depressive patients. Vitamin D deficiency is significantly associated with cognitive/affective symptoms of depression, but less with somatic/affective ones. Patients with Vitamin D deficiency had more depressive symptoms than those with Vitamin D insufficiency, while patients with insufficient Vitamin D had higher cognitive/affective symptom scores than those with sufficient Vitamin D.

Vitamin D supplementation with at least 800 I.U. daily is favorable in the management of depression [34] and may increase the effect of antidepressants in major depressive disorder patients [35]. There is current evidence that adjunctive use of Vitamin D with antidepressants can reduce depressive symptoms more effectively [36]. Song et al., [37] and Wang et al., [38] found that Vitamin D supplementation is effective in the treatment of depression and in lowering the depressive symptoms.

Neurobiological and neuroendocrine mechanisms have been suggested for the link between Vitamin D deficiency and depressive symptoms. Vitamin D has a role in brain areas processing depressive mood [39], in dopaminergic and serotonergic function [40,41], and in constraining systematic inflammation being associated with depression [42].

In this study, serum urea concentrations are significantly increased in depressive patients compared to healthy controls, but they are within the normal range. Some antidepressants are kidney toxic, such as lithium, and damage the kidney of the patients elevating the urea level in blood [43].

The findings of the present study showed no significant differences in the serum TSH between individuals with depression and healthy controls. Their measures were within the normal range. Overt or subclinical thyroid disease was one of the exclusion criteria in the current study. Thyroid hormones (FT3 and FT4) are distributed widely in the central nervous system. They play a role in the development of cerebellum and cerebral cortex [44] and regulation of neural growth [45]. Studies have reported that depression is associated with changes in the Hypothalamic-Pituitary-Thyroid (HPT) axis [46] and there is a positive correlation between depression and overt hypothyroidism [47]. It was also reported that there is an association of diagnosis of depression in hospitalized patients.
Vitamin D deficiency with hypothyroidism and that Vitamin D is inversely related to TSH [48].

The results of liver enzymes (AST and ALT) were also within the normal range and there were insignificant differences between individuals suffering depression and healthy controls. Patients with liver diseases were excluded from this study as Vitamin D deficiency has been reported in previous studies to be associated with chronic liver diseases [49] and chronic hepatitis C virus infection [50].

In the present study, it has been shown that depressive psychotic patients suffered from Vitamin D deficiency or insufficiency. Therefore, assessment and supplementation of Vitamin D should be a routine in the treatment of depressed patients, as a promising new approach in treating depression. On the other hand, maintaining optimum Vitamin D levels is highly favorable in preventing depression.

References


44. CHATONNET F., PICOU F., FAUQUIER T. and FLA-


